4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

SC 13G - Vor Biopharma Inc. (0001817229) (Subject)

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.  "We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our cl

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trialsDespite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data, which was presented at the TANDEM Me

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFireside Chat: Wednesday, February 12th at 12:00pm ET Location: Virtual A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the PIPE) that is expected to result in gross proceeds of approximately $55.6 million, before deducting placement agent

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host 1x1 investor meetings at the Stifel 2024 Healthcare Conference. Stifel 2024 Healthcare Conference Fireside Chat: Monday, November 18, 2024 at 2:25 pm ETLocation: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update.  "We are pleased with our operational and clinical execution this quarter and look forward to sharing additional clinical data since our September data update at the ASH annual meeting in December," said Dr. Robert Ang, Vor Bio

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio's approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology

Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children's Hospital of Philadelphia, to discuss abstracts today, November 2, at 9.30 AM ET. CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the Company's novel platform and approach for treating acute myeloid leukemia (AML), will be presented at the 65th American Society of Hem

Strong progression of PureTech's Wholly Owned Pipeline, with three clinical-stage therapeutic candidates being evaluated across four clinical trials to address large patient needs in pulmonary, oncology and CNS indications, and a growing pipeline of four additional preclinical CNS programs Advancements across Founded Entities, including Karuna's third positive registrational trial for KarXT and planned filing for FDA approval, Akili's commercial release of EndeavorOTCTM for adults with ADHD, Gelesis' application to make Plenity® available without a prescription, additional positive results from Vor's Phase 1/2a leukemia trial and Vedanta's $106.5 million financing PureTech plans to purs

Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023.U.S. FDA clears VCAR33ALLO IND.Conference call scheduled for today, June 9 at 8:30am ET. CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML). These data were presented by Guenther K

Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO on track for IND submission in first half of 2023$116M financing extends expected cash runway into Q1 2025 CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update.  "We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study," said Dr. Robert Ang,

Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or "trem-cel" (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactu

Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

HC Wainwright & Co. initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $26.00

Robert W. Baird initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $38.00

Baird initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $38.00

Oppenheimer initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $30.00

JMP Securities initiated coverage of Vor Biopharma with a rating of Market Outperform and set a new price target of $40.00

B. Riley Securities initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $60.00

Barclays initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $56.00

The Goldman Sachs Group initiated coverage of Vor Biopharma with a rating of Sell and set a new price target of $19.00

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience to the position, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. "This is a time of tremendous momentum for Vor Bio with initial data expected later this year for our ongoing clinical trial of VOR33, and as we work towards our IND submission for VCAR33ALLO in the first half of next year," said Dr. Robert Ang, Vor Bio's President a

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to actively recruit patients into VBP101, the Company's Phase 1/2a first-in-human study of VOR33 in patients with AML who are at high risk of relapse. An executive search to replace Dr. Slapak is underway. "Our plan has always been for Dr. Slapak to build a team and infrastructure to successfully initiate the VBP101 clinical trial," said Dr. Robert Ang, President & Chief Executive Officer, Vor Bio. "Now that w

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's Senior Vice President of Program and Alliance Management. Dr. Schmelmer has more than 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders and infectious diseases at leading biopharmaceutical companies. Dr. Schmelmer will oversee the management of Vor's key programs, leading cross-functional teams across the organization and working with external collaborators to advance the company's mission to change the standard of care for patients with blood

On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated build-out of in-house clinical manufacturing facility CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2021, and provided a business update.  "Vor is pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted cancer therapies, and this quarter, we made several important advancements towards the clinic, and expanded our platf